Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...
Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
1d
Zacks Investment Research on MSNBiotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant ...
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.
BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $20 from $82 and keeps an Outperform rating on the ...
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...
Arvinas and Pfizer will share the costs and profits of the development and commercialization of vepdegestrant, which has ...
Arvinas (ARVN) and Pfizer (PFE) announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus ...
The 624-subject global study evaluated patients’ progression-free survival (PFS) as a primary endpoint in the intent-to-treat and estrogen receptor 1-mutant (ESR1m) populations, while their ...
Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results